Changing costs of metastatic non small cell lung cancer in the Netherlands
Autor: | Keusters, W R, de Weger, Vincent A, Hövels, A, Schellens, J H M, Frederix, G W J, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
---|---|
Přispěvatelé: | Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Male
Cancer Research Lung Neoplasms medicine.medical_treatment 0302 clinical medicine Cost of Illness Non-small cell lung cancer Carcinoma Non-Small-Cell Lung Outcome Assessment Health Care Disease management 80 and over 030212 general & internal medicine Non-Small-Cell Lung Case report form Average cost Netherlands Aged 80 and over Health Policy Disease Management Health Care Costs Middle Aged Oncolytic drugs Oncology Cost driver 030220 oncology & carcinogenesis Healthcare policy Cost of illness Female Immunotherapy Pulmonary and Respiratory Medicine Adult medicine.medical_specialty Antineoplastic Agents 03 medical and health sciences Outcome Assessment (Health Care) Internal medicine medicine Journal Article Humans Intensive care medicine Lung cancer Aged Retrospective Studies business.industry Carcinoma Cancer Retrospective cohort study Length of Stay medicine.disease Oncolytic virus Radiation therapy business Delivery of Health Care |
Zdroj: | Lung Cancer, 114, 56. Elsevier Ireland Ltd Lung Cancer, 114, 56. Elsevier Ireland Ltd. |
ISSN: | 0169-5002 |
Popis: | Objectives The primary objective of this study was to identify the total intramural cost of illness of metastatic non-small cell lung cancer (NSCLC) in the Netherlands between 2006–2012. Secondary objective was to identify whether changes in cost patterns of metastatic NSCLC have occurred over the last years. Methods Patients diagnosed with metastatic NSCLC between 1-1-2006 and 31-12-2012, who had follow-up to death or the date of data cut-off and no trial participation were included. A structured chart review was performed using a case report form. Data collection started after diagnosis of metastatic NSCLC and ended at death or April first, 2015. Data regarding outpatient visits, clinical attendance, oncolytic drug use, imaging, lab tests, radiotherapy and surgery were collected. Results Sixty-seven patients were included with a median age of 67 years. The median follow-up was 234 days. On average patients had 28 outpatient visits and 11 inpatient days. Oncolytic drugs were administered to 76% of the patients. Mean per patient expenditures amounted up to €17,463, with oncolytic drugs (€6,390) as the main cost driver. In comparison with the time-period of 2003–2005 total per patient per year expenses decreased by 44%. The contribution to total yearly costs of oncolytic drugs increased from 18% to 35%, while costs for inpatient stay decreased from 52% to 28% of total expenditures. Conclusion Outcomes in this study demonstrate that average treatment costs for metastatic NSCLC in the Netherlands Cancer Institute amount to €17,463. Compared to a prior study the average cost for metastatic NSCLC over time in the Netherlands has decreased. A shift of main cost drivers seems to have occurred from inpatient stay, to oncolytic drugs as main contributor. The shift towards treatment cost might become more visible with the introduction of immunotherapy. These results mark the importance of up-to-date cost of illness studies. |
Databáze: | OpenAIRE |
Externí odkaz: |